Brick & Kyle Associates bought a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,703 shares of the company's stock, valued at approximately $2,087,000.
A number of other institutional investors also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $8,407,908,000. Proficio Capital Partners LLC grew its position in Eli Lilly and Company by 100,387.1% in the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock worth $4,016,110,000 after purchasing an additional 5,197,038 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after purchasing an additional 2,012,129 shares during the period. Capital International Investors raised its position in Eli Lilly and Company by 23.2% in the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock worth $6,740,272,000 after purchasing an additional 1,645,222 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $1,240,653,000. Institutional investors and hedge funds own 82.53% of the company's stock.
Eli Lilly and Company Stock Performance
NYSE:LLY traded up $11.03 during mid-day trading on Tuesday, hitting $724.74. The company's stock had a trading volume of 3,786,668 shares, compared to its average volume of 3,623,076. The stock has a market cap of $686.86 billion, a price-to-earnings ratio of 61.89, a PEG ratio of 1.40 and a beta of 0.48. The business's fifty day moving average is $786.82 and its two-hundred day moving average is $802.40. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.58 earnings per share. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.
Eli Lilly and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on LLY shares. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Citigroup reduced their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.37.
View Our Latest Stock Analysis on Eli Lilly and Company
Insider Activity
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.13% of the company's stock.
Eli Lilly and Company Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles

Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report